Last reviewed · How we verify
Naoxintong Capsule
Naoxintong Capsule is a Traditional Chinese Medicine (herbal formulation) Small molecule drug developed by Chinese Academy of Medical Sciences, Fuwai Hospital. It is currently FDA-approved for Angina pectoris, Myocardial infarction prevention and treatment, Cerebral infarction and stroke prevention. Also known as: Chinese Herbal Compound, NXT group.
Naoxintong Capsule is a traditional Chinese medicine formulation that improves blood circulation and reduces blood stasis to treat cardiovascular and cerebrovascular conditions.
Naoxintong Capsule is a traditional Chinese medicine formulation that improves blood circulation and reduces blood stasis to treat cardiovascular and cerebrovascular conditions. Used for Angina pectoris, Myocardial infarction prevention and treatment, Ischemic stroke.
At a glance
| Generic name | Naoxintong Capsule |
|---|---|
| Also known as | Chinese Herbal Compound, NXT group |
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
| Drug class | Traditional Chinese Medicine (herbal formulation) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
The capsule contains multiple herbal components that work synergistically to promote blood flow, reduce platelet aggregation, and improve microcirculation. It is believed to work through multiple pathways including anticoagulation, vasodilation, and anti-inflammatory mechanisms, though the exact molecular targets have not been fully characterized in Western pharmacological terms.
Approved indications
- Angina pectoris
- Myocardial infarction prevention and treatment
- Cerebral infarction and stroke prevention
Common side effects
- Gastrointestinal upset
- Dizziness
- Headache
Key clinical trials
- A Study for Exploring the Efficacy of Naoxintong Capsules in the Treatment of Coronary Atherosclerotic Plaque on the Basis of Optimal Medical Therapy (Aspirin,Statins,Clopidogrel, Etc.): Stage One (NA)
- Curative Efficacy of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM (PHASE4)
- Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naoxintong Capsule CI brief — competitive landscape report
- Naoxintong Capsule updates RSS · CI watch RSS
- Chinese Academy of Medical Sciences, Fuwai Hospital portfolio CI
Frequently asked questions about Naoxintong Capsule
What is Naoxintong Capsule?
How does Naoxintong Capsule work?
What is Naoxintong Capsule used for?
Who makes Naoxintong Capsule?
Is Naoxintong Capsule also known as anything else?
What drug class is Naoxintong Capsule in?
What development phase is Naoxintong Capsule in?
What are the side effects of Naoxintong Capsule?
Related
- Drug class: All Traditional Chinese Medicine (herbal formulation) drugs
- Manufacturer: Chinese Academy of Medical Sciences, Fuwai Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Angina pectoris
- Indication: Drugs for Myocardial infarction prevention and treatment
- Indication: Drugs for Cerebral infarction and stroke prevention
- Also known as: Chinese Herbal Compound, NXT group
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing